LGBTQ+ health centers lead fight against mpox and stigma nationwide
Matt Alderton
Studio Gannett
The date was May 17, 2022. It was more than two years into the COVID-19 pandemic, and Americans everywhere were epidemiologically exhausted. In Massachusetts, however, public health officials had just clocked the first case in a brand-new infectious disease outbreak.
The pathogen now known as mpox was first documented in monkeys in 1958. Caused by a virus similar to the smallpox virus, it causes flu-like symptoms; a painful, pustulous rash; and, in the rarest cases, death.
When the U.S. Department of Health and Human Services (HHS) declared mpox a public health emergency in August 2022, there were more than 10,000 documented cases in the United States — mostly in the LGBTQ+ community, where the virus had spread rapidly through sexual transmission. Cases slowly declined from there, however, and by January 2023 the threat had mostly faded.
Credit for the containment belongs not only to the LGBTQ+ individuals who embraced safer sex practices and stood in blocks-long lines for vaccines, but also to the doctors and nurses at community health centers who delivered critical care and education tailored to at-risk patients.
'LGBTQ+ clinics and community centers were the first to respond and set up very quickly and very efficiently not only information for our community to keep us safe, but also vaccine programs,' says Alex Sheldon , executive director of GLMA, previously known as the Gay & Lesbian Medical Association. 'The (U.S. Centers for Disease Control and Prevention) had raised huge alarm bells about where this was going to go, and that it was going to spread even further into the general population. But because of the quick and efficient responses of these clinics and community centers, and because of the trust they already had with community members, they were able to respond so quickly that it for the most part stopped mpox in its tracks.'
Need a break? Play the USA TODAY Daily Crossword Puzzle.
The rapid, responsive care that LGBTQ+ community health centers provided during mpox is the same care they provided during COVID-19 and the HIV/AIDS crisis decades prior. More important, it's the same care they provide daily to LGBTQ+ individuals who need routine services like primary and preventive care, screening for sexually transmitted infections (STIs) and mental health counseling.
'Many LGBTQ+ clinics were started by LGBTQ+ providers who had a stake in their community's wellbeing. So, they developed health care settings that were designed around their own needs,' Sheldon says. 'These places center our community within every single part of what they do.'
Unique Health Needs
Because LGBTQ+ people have unique health care needs, it's critical that health care systems are tailored to those needs.
'LGBTQ+ people … experience a lot of health disparities, and the vast majority of those health disparities are driven by the pronounced stigma and discrimination that LGBTQ+ people face in our everyday lives,' explains Sheldon, who says stigma creates stress that can impact both mental and physical health. 'Navigating a world that isn't built for you because it's designed around cisgender and heterosexual experiences —who your partner is, what you do on the weekends, how you built your family — can be a really challenging way to live.'
LGBTQ+ people who have experienced discrimination often go out of their way to avoid it in the future, which might mean delaying health care or opting out of it entirely to evade providers with whom they don't feel seen or safe.
'The longer you delay getting health care … the more likely you are to have adverse health outcomes because of that delayed care,' Sheldon says.
Therein lies the merit of community health centers, says Dr. Stephen Abbott , medical site director of the Max Robinson Center at Whitman-Walker, a nonprofit community health system serving LGBTQ+ patients in Washington, D.C.
'Often, issues surrounding an individual's care don't get disclosed if somebody doesn't feel comfortable in the environment where they're seeking care,' Abbott says. 'If you go into a waiting room and there's nobody there affirming your pronouns, or they make certain assumptions about who your partner is, or they can't take a decent sexual history, or they don't know how to do an appropriate mental health screening that's informed by traumatic experiences in your past, then you're not going to get appropriate care.'
Community health centers make LGBTQ+ patients comfortable by fostering inclusion in every respect — having gender-neutral intake forms, hiring medical and administrative staff from the community, offering LGBTQ+ periodicals in waiting rooms and depicting LGBTQ+ individuals on websites and in patient literature, all of which foster trust so that patients are more likely to show up for appointments, seek preventative care and adhere to medical advice and guidelines.
'Community health centers that have historically served the LGBTQ+ community have demonstrated the ability to look past a person's sexual or gender identity and see them as a whole person,' says Dr. Travis Gayles , CEO of Howard Brown Health, a nonprofit community health system serving LGBTQ+ patients in Chicago. 'And when you're seeing the whole person, you can gain new perspectives and insights, ask appropriate questions, offer appropriate treatment and, ultimately, create better health outcomes.'
Community health centers like Whitman-Walker and Howard Brown are particularly proud of the care they provide for individuals with HIV; preventative services like pre-exposure prophylaxis (PrEP) and Doxycycline post-exposure prophylaxis (Doxy PEP) for HIV and STI prevention, respectively; and their provision of gender-affirming care to individuals who are trans and nonbinary. To measure their success, however, they rely as much on social and emotional metrics as clinical ones.
Holistic Care
'There are folks who have come to us for mpox, for HIV treatment or for gender-affirming care who have moments of pure joy and gratitude that you can't measure with the resolution of a rash, a viral load or even completion of a transition,' Abbott says.
Gayles concurs. 'Yes, we look at clinical outcomes. But what's also important is empowering patients with stable housing, academic opportunities and employment opportunities. … When you're going to a health center like ours that understands all those (social determinants of health), it increases the likelihood that you're going to be connected in a meaningful way to those services.'
'We'll Get Through This'
Both the LGBTQ+ community and the health centers that serve it are experiencing significant challenges, according to Sheldon, who notes that the Trump administration budget proposes significant reductions in funding and support for sexual and gender minorities. HHS, for example, has closed its Office of Minority Health; the Centers for Disease Control and Prevention is considering closing its Division of HIV Prevention; the National Institutes of Health has terminated more than 270 grants focused on LGBTQ+ health research, worth at least $800 million; and Congress is mulling significant cuts to Medicaid, on which many community health centers rely.
'Our health systems are under attack, but … I remain incredibly optimistic,' Sheldon says. 'When (governments) say we are invisible or worthy of erasure, we have always risen to the occasion by caring for ourselves and each other … We are once again rising to the occasion and will not back down.'
Utilizing community health centers for services, donating to them, and singing their praises to philanthropists and policymakers can help fuel the fight, Abbott adds. 'We're going to be here no matter what,' he says. 'We'll get through this.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
The cost of staying alive could become a lot more expensive for millions of Americans because of Trump drug tariffs
Americans would likely pay more for necessary everyday prescription drugs, such as insulin, painkillers, chemotherapy, or antibiotics, if President Donald Trump were to enact tariffs on pharmaceuticals, experts warn. In an effort to incentivize drug manufacturers to bring production back to the United States, Trump has proposed tariffing pharmaceuticals made overseas – which account for an overwhelming majority of everyday medicine used in the U.S. 'We're going to be doing that,' Trump said of pharmaceutical tariffs in April. 'That's going to be like we have on cars. You know we have a 25 percent tariff on cars, we have a 25 percent tariff on steel and aluminum, and that's what the [pharmaceutical] category fits right now.' 'The higher the tariff, the faster they come,' Trump said. But experts say that's not necessarily true and there would be tangible consequences to such action, from higher brand-name drug prices to generic drug shortages. 'If tariffs were applied to prescription drugs, one of the most immediate consequences could be price increases — on prices that we already pay way in excess of other countries,' Dr. Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, said. The U.S. imports a majority of its branded prescription drugs – or medications that are patented with a brand name such as Viagra, Wegovy, or Zoloft – from high-income countries. Dr. Jeromie Ballreich, an associated research professor at Johns Hopkins Bloomberg School of Public Health, said much of the manufacturing comes from Ireland, Germany, and Switzerland because they have favorable tax policies for companies. As a result, adding a tariff would only make it more expensive for pharmacies and insurance companies to keep them in supply. 'We would expect pharma to pass the costs onto the insurers and we would expect insurers to pass the cost onto the individual patients,' Ballreich said. 'So, if there is a 50 percent tariff on your insulin product because it's coming from Ireland, patients in Mississippi who get insulin – they will either be faced with a higher cost when they go up to the pharmacy to fill their insulin or they're going to face a higher indirect cost because the premiums of the insurance plan are going to go up,' he said. Ballreich said a tariff on countries that produce high quantities of branded drugs would put 'pressure' on public insurers like Medicare or Medicaid and private insurers. However, branded drugs only account for roughly 10 to 15 percent of prescriptions. A majority of Americans, up to 90 percent, use generic drugs, often manufactured in India and China, because they're cheaper. Making branded drugs less accessible through tariffs would only increase reliance on generic drugs, which could exacerbate shortages that already impact millions of Americans. '[Shortages] can have very significant implications in day-to-day clinical practice,' Socal said. 'For example, if you are administering chemotherapy for an oncology patient, that may have significant consequences even for the prognosis of that case moving forward.' In 2024, the U.S. experienced a shortage of more than 300 drugs – 70 percent of which were generic prescriptions. Socal said that when patients are not able to access a more affordable version of their prescription, it means they may put their health at risk by skipping a dosage, taking a lower dosage, or not filling their prescription at all. Otherwise, they're forced to turn to the more expensive branded version. 'Those more expensive drugs are not always the best,' Socal said. 'Very frequently, and we saw this with chemotherapy shortages, the available drugs are second-line drugs.' The president has indicated that any negative impact from tariffs may be temporary and worth it to bring manufacturing and jobs back. 'We're doing it because we want to make our own drugs,' Trump said. But Ballreich and Socal are more skeptical. 'Tariffs are a very blunt instrument to incentivize domestic U.S. manufacturing of the branded drugs we use,' Ballreich said. Given pharmaceutical companies have moved outside of the U.S. for tax purposes, Ballreich says tax policy may be a better way to incentivize them, especially since many of those drugs are more difficult to manufacture. 'It's not just a very simple chemical plant; these tend to be very complex,' he said. Socal suggested a better strategy would be to understand where drugs are being manufactured and which ones would make more sense to bring to the U.S. — since even those manufactured locally often rely on certain imported ingredients and materials. 'Having tariffs on pharmaceutical products coming from abroad can actually also hurt our domestic manufacturers,' he says. While the president has not officially implemented any tariff policy on pharmaceuticals yet, he said, in April, that the plan would take effect in the 'not too distant future.'

Yahoo
an hour ago
- Yahoo
The reasons aren't fully clear, but overdose deaths are down in Kern, US
Overdose deaths, specifically from opioids, are on the decline across the nation and data from the Kern County Coroner's Office shows local deaths are down as well. According to KCSO, there were 189 fentanyl-related overdose deaths in Kern County in 2024, down from 297 in 2023, a roughly 36% decline. The decline is part of a broader trend nationally. Opioid overdose deaths declined sharply from 2023-2024, according to provisional data from the Centers for Disease Control and Prevention. According to the CDC, 48 states and the District of Columbia all saw decreases in overdose deaths from December 2023 to 2024, a 26% decrease nationwide. California's reported overdose deaths dropped by 24%, the most of any West Coast state. Only Nevada and South Dakota saw an increase in overdose deaths, both by less than 4%. It's not entirely clear what's driving the decline, and experts are pointing to a range of factors. "Over the past, I'd say this calendar year, we have seen an increase in the people who are coming into our treatment system," said Ana Olvera, an administrator with Kern Behavioral Health and Recovery Services. "More people have accessed our treatment system than in years past, even coming out of COVID, which is a good sign for us," Olvera said. The increased availability of treatment programs and the overdose reversal drug naloxone were likely contributors to the decrease, she said, as well as reduced stigma about seeking treatment. Olvera also pointed to the passage of Proposition 36, which increased penalties for certain crimes. "Just from that — working with the courts and people who are eligible for this program that have a treatment-mandated felony — we have seen an increase of folks who are eligible and who come into our system of care," Olvera said. BHRS and other health care providers have increased their treatment options, Olvera said. The county's 24-hour substances-use-disorder hotline, which helps connect people with treatment, has seen higher call volume over the years, she said. "The call center is how most people access treatment in our substance use system," Olvera said. The average number of calls has increased from 908 in the 2018-2019 fiscal year to 1,272 in 2023-2024. From July 2024 to April of this year, there were 1,061 calls. There's no doubt overdose deaths are dropping, but exactly why is still a matter of conjecture. The Opioid Data Lab at the University of North Carolina at Chapel Hill tracks information related to opioids and its researchers have said there's no single explanation for such a steep, nationwide decline in overdose deaths. "Ascribing a single national explanation for the drop in overdoses is not grounded in data," the lab said in a February analysis. Even with the large decline in deaths, the mortality rate from drug overdoses remains high, with most states still recording death rates higher than before the COVID-19 pandemic. Data from the CDC and the California Department of Public Health shows overdose deaths peaking in 2023 before dropping sharply in 2024. According to CDPH, Kern County's opioid-related overdose deaths reached an all-time high of 321 in 2023. That was up from 308 in 2022 and 274 in 2021. As of April 30, Kern had seen 50 fentanyl-related deaths so far this year, according to KCSO.
Yahoo
an hour ago
- Yahoo
RFK Jr.'s HHS Shakeup Spares Dr. Plescia, Backer Of Vaccine Credentials
Despite firing every member of the federal vaccine advisory committee, Health and Human Services Secretary Robert F. Kennedy Jr. has retained one key figure with a radically pro-passport past. Kennedy, who recently disbanded the Advisory Committee on Immunization Practices (ACIP), kept Dr. Marcus Plescia in a top post at HHS as Deputy Assistant Secretary and Director of the Office of Science and Medicine. Plescia's past comments in favor of vaccine passports place him well to the left of even the Biden White House's stance during the height of the COVID-19 pandemic. In 2021, Plescia — then serving as chief medical officer for the Association of State and Territorial Health Officials — told The New York Times that vaccine passport credentials were 'going to be necessary,' calling it 'perplexing' that the federal government was keeping its distance from such a proposal. His remarks came even as White House Press Secretary Jen Psaki assured reporters that 'there will be no federal vaccinations database and no federal mandate requiring everyone to obtain a single vaccination credential.' Plescia's position, made public at the time through The New York Times' reporting, stood in contrast not only to Biden's hesitancy but also to an ongoing wave of state-level opposition. Governors from Texas, Florida, and Mississippi issued orders banning or opposing any form of vaccine credentialing, arguing it violated basic liberties and privacy. Kennedy's implicit decision to retain contrasts with his other decisions. On June 9, the new health secretary made headlines for his sweeping removal of the 17-member ACIP panel, citing what he called a 'crisis of public trust' caused by conflicts of interest and pharmaceutical industry influence. 'The committee has become… little more than a rubber stamp for any vaccine. It has never recommended against a vaccine—even those later withdrawn for safety reasons.' Kennedy wrote in an op-ed for The Wall Street Journal, adding that many members had received 'substantial funding from pharmaceutical companies.' But the retention of Plescia — whose support for vaccine passports predates the Biden administration's relatively more cautious approach — raises questions. Plescia's 2021 endorsement of vaccine credentials aligned more with European-style digital health passes and apps like those trialed by Cathay Pacific Airlines and implemented by companies such as Walmart. 'There is going to have to be some kind of system where [vaccination status] is verified,' he said, arguing it was the only way to safely reopen businesses and restore public trust. The White House was unwilling to go that far at the time, concerned about the ethical implications and civil liberties involved. Instead, Psaki emphasized the government's position that any such system should 'meet key standards, including accessibility, affordability and privacy,' but would ultimately be left to the private sector. President Biden never fully implemented a vaccine passport system, but he did issue an executive order requiring nearly every private sector employee to get the COVID shot, which in turn prompted companies to create systems of verification for employees and customers. RFK Jr., a longtime COVID vaccine critic, ran a presidential campaign and later accepted his appointment to HHS on promises to dismantle what he called medical 'fascism.' His decision to purge the ACIP panel came after immense pressure from MAHA allies, including Dr. Mary Talley Bowden of Houston, who slammed the secretary for not taking more aggressive policy action to date, The Dallas Express reported. Kennedy's shakeup alarmed some congressional figures. Sen. Bill Cassidy (R-LA), a physician, said, 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion. I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case.' Kennedy was contacted for comment in the production of this story, but he did not respond. A spokesman for HHS did not immediately respond. Plescia's HHS bio describes his duties as follows: 'He advises the Assistant Secretary and OASH leadership across scientific and medical issues covering the full suite of public health priorities. He oversees staff and program work focused on state and federal health systems, infection-associated chronic conditions, vector borne disease, data-driven decision making and healthcare innovation.' The bio qualifies him for the job by saying, '[He] has widespread experience in medicine and public health. He is Board Certified in Family Medicine and practiced for over 20 years in a variety of settings serving homeless, urban poor and rural underserved populations.'